People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kleo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $34.7M | $721.1M | 2016 |
Roy Prieb at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roy Prieb on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Declan Doogan | 1 | 6 |
| John W. Childs | 1 | 4 |
| Alexander Goor | 1 | 2 |
| David Spiegel | 1 | 2 |
| Douglas Manion | 1 | 1 |
| Charles G. Drake | 1 | 1 |
| Douglas G. Manion | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.